Antithrombotic Therapy After Coronary Artery Stenting in Patients With Atrial Fibrillation

substantially higher than the 1% to 6% rate reported in contemporary cohorts of stented patients with AF. 9 Compared with patients who had an HAS-BLED score of 1 to 2, those with a score >3 had substantially higher rates of mortality (14.1% versus 7.3%, P=0.04) and major adverse cardiovascular events (18.9% versus 8.8%, P 3, those discharged home on warfarin (most of whom were receiving triple therapy) had an 80% lower adjusted hazard of death (HR 0.20; 95% CI: 0.06–0.64) and a 79% lower adjusted hazard of major adverse cardiovascular events (hazard ratio: 0.21; 95% CI: 0.08–0.57) than those not discharged home on warfarin. Patients discharged home on warfarin also had a higher rate of bleeding than those not discharged on warfarin but this is not unexpected, and the increased hazard of bleeding was no longer statistically significant in the adjusted analyses (hazard ratio: 2.31; 95% CI: 0.55–9.71).